Overview

• Clinical trials in South Africa and Uganda found zero new HIV infections among participants receiving the twice-yearly injection compared with a 2 percent infection rate in daily oral PrEP users.
• Yeztugo (lenacapavir) inhibits HIV at multiple stages of its lifecycle and shows no cross-resistance with existing antiviral classes.
• The long-acting injection, named Discovery of the Year 2024 by Science, addresses adherence challenges posed by daily HIV-prevention pills.
• Gilead has committed to a fast US launch and partnerships for wider distribution in high-prevalence regions, including sub-Saharan Africa and developing countries.
• President Trump’s proposed federal funding cuts to HIV prevention programs could jeopardize rollout and research support critical to curbing the epidemic.